Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Jane Street Group LLC

Jane Street Group LLC cut its stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 71.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 42,272 shares of the company’s stock after selling 103,504 shares during the quarter. Jane Street Group LLC owned approximately 0.06% of Ventyx Biosciences worth $92,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of VTYX. Deerfield Management Company L.P. Series C increased its holdings in shares of Ventyx Biosciences by 64.6% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock valued at $13,466,000 after purchasing an additional 2,287,570 shares in the last quarter. Sio Capital Management LLC grew its position in Ventyx Biosciences by 153.2% during the third quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock valued at $4,299,000 after buying an additional 1,193,024 shares during the period. Vestal Point Capital LP increased its holdings in Ventyx Biosciences by 31.2% in the third quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $3,760,000 after buying an additional 410,000 shares in the last quarter. State Street Corp raised its position in shares of Ventyx Biosciences by 0.8% in the third quarter. State Street Corp now owns 1,187,650 shares of the company’s stock worth $2,589,000 after acquiring an additional 9,783 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its stake in shares of Ventyx Biosciences by 19.5% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 568,479 shares of the company’s stock worth $1,239,000 after acquiring an additional 92,753 shares in the last quarter. 97.88% of the stock is owned by institutional investors and hedge funds.

Ventyx Biosciences Trading Down 0.5 %

Shares of VTYX opened at $1.94 on Wednesday. The firm has a market cap of $137.18 million, a PE ratio of -0.82 and a beta of 0.55. The company’s 50 day simple moving average is $2.29 and its 200-day simple moving average is $2.28. Ventyx Biosciences, Inc. has a 12-month low of $1.67 and a 12-month high of $11.48.

Insiders Place Their Bets

In related news, CEO Raju Mohan purchased 238,248 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was purchased at an average price of $1.83 per share, with a total value of $435,993.84. Following the completion of the transaction, the chief executive officer now owns 1,913,276 shares of the company’s stock, valued at approximately $3,501,295.08. This trade represents a 14.22 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John Nuss sold 13,161 shares of the firm’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $2.26, for a total value of $29,743.86. Following the completion of the transaction, the insider now owns 485,701 shares in the company, valued at approximately $1,097,684.26. This trade represents a 2.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders acquired 630,000 shares of company stock worth $1,262,415. 18.18% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on VTYX. HC Wainwright reaffirmed a “neutral” rating on shares of Ventyx Biosciences in a research note on Tuesday. Oppenheimer reissued an “outperform” rating and issued a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Ventyx Biosciences has an average rating of “Moderate Buy” and an average target price of $10.00.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.